NTRK1 and renal cell adenocarcinoma: Furthermore, preliminary results of phase I/II trials of the multi-cohort COSMIC-312 trial has demonstrated promising potential of cabozantinib, a multi-receptor tyrosine kinase (TKI) inhibitor with VEGF inhibitory activity in combination with atezolizumab in metastatic HCC, non-small cell lung cancer, renal cell cancer (RCC), and prostate cancer [14–17].